Hitachi Chemical inks Daiichi Sankyo regenerative meds deal

By Flora Southey contact

- Last updated on GMT

Daiichi Sankyo has selected CDMO Hitachi Chemical Therapeutics Solutions to make regenerative medicine for the Japanese market.

Under the clinical manufacturing agreement, Hitachi Chemical will make Daiichi Sankyo’s investigative product at its facility in Yokohama City, Kanagawa Prefecture.

The site houses Hitachi Chemical’s PCT regenerative cell-focused service platform, which its off-shoot Hitachi Chemical Co. America purchased​ from majority shareholder Caladrius Biosciences last year.

Regenerative medicine describes the process of transplanting in-vitro ​cells into patients to help restore organ or immune functions affected by disease. Regenerative approaches include immunotherapy and somatic stem cell therapies, engineered immune cell therapy and induced pluripotent stem cells (iPSC).

Daiichi Sankyo spokesperson Koji Ogiwara did not disclose which investigational drug will be manufactured by Hitachi Chemical, nor did he provide details on the manufacturing timeframe.

In October last year, Hitachi Chemical announced plans​ to add 49,700 sq. ft. to its PCT service site in Allendale, New Jersey, US.

The firm also announced plans to upgrade its Pearl Court site in Allendale, and confirmed its regenerative cell-focused CDMO site in Yokohama would be validated by April this year.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more